Suppr超能文献

硝唑尼特与阿苯达唑单剂量及三日疗法治疗肠道寄生虫的疗效比较

[Nitazoxanide vs albendazole against intestinal parasites in a single dose and for three days].

作者信息

Belkind-Valdovinos Uri, Belkind-Gerson Jaime, Sánchez-Francia Domingo, Espinoza-Ruiz Mónica Marcela, Lazcano-Ponce Eduardo

机构信息

Facultad de Medicina, Universidad Nacional Autónoma de México, México, DF, México.

出版信息

Salud Publica Mex. 2004 Jul-Aug;46(4):333-40. doi: 10.1590/s0036-36342004000400008.

Abstract

OBJECTIVE

To assess the effectiveness of the usual dose of nitazoxanide administered for three days and as a single dose for massive eradication of intestinal parasites in the pediatric population, compared with single-dose albendazole.

MATERIAL AND METHODS

A randomized clinical trial was conducted in three rural communities in central Mexico City between 2001 and 2003 to assess three possible therapy regimes in a study population of 786 children 5 to 11 years of age, 92 of whom had a positive parasitology test result (15.1%). Group 1 included 27 patients treated with 400 mg given as a single dose of albendazole; group 2 included 34 patients whose therapy consisted of a 15 mg/kg/day dose for three consecutive days; patients in group 3 (n=31) were administered a single 1.2 g dose of nitazoxanide. Differences in proportions were assessed using Fisher's exact test.

RESULTS

No statistically significant differences were found in the effectiveness of the three treatment regimes: 80.5% with albendazole, compared with the two nitazoxanide alternatives (67.6% and 71%, respectively.A higher prevalence of side effects was observed with nitazoxanide in the three-day regimen (26.5%) and as a single dose (32.2%), compared with a single dose of albendazole (7.4%).

CONCLUSIONS

According to the evidence on effectiveness and side effects, the use of nitazoxanide is not justified as a massive prophylactic medication for intestinal parasitosis control alternative in endemic areas. In countries with a high prevalence of intestinal parasitosis primary prevention measures should be the most important strategy, together with public sanitation, drinking water and sewage system availability, water chlorination, and appropriate animal fecal waste disposal, as well as health education.

摘要

目的

评估常规剂量的硝唑尼特连续服用三天及单次大剂量给药用于大规模根除儿科人群肠道寄生虫的有效性,并与单剂量阿苯达唑进行比较。

材料与方法

2001年至2003年在墨西哥城中部的三个农村社区进行了一项随机临床试验,以评估786名5至11岁儿童研究人群中的三种可能治疗方案,其中92人寄生虫学检测结果呈阳性(15.1%)。第1组包括27名接受400毫克单剂量阿苯达唑治疗的患者;第2组包括34名连续三天接受15毫克/千克/天剂量治疗的患者;第3组(n = 31)的患者接受单次1.2克剂量的硝唑尼特治疗。使用Fisher精确检验评估比例差异。

结果

三种治疗方案的有效性未发现统计学上的显著差异:阿苯达唑的有效率为80.5%,与两种硝唑尼特方案(分别为67.6%和71%)相比。与单剂量阿苯达唑(7.4%)相比,硝唑尼特在三天疗程(26.5%)和单次给药(32.2%)时观察到更高的副作用发生率。

结论

根据有效性和副作用的证据,硝唑尼特作为流行地区控制肠道寄生虫病的大规模预防性药物替代品是不合理的。在肠道寄生虫病高发国家,初级预防措施应是最重要的策略,同时包括公共卫生、饮用水和污水系统供应、水氯化处理、适当的动物粪便处理以及健康教育。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验